Matthew D. Shaines

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/23962180-4f0f-11ef-97ac-c3191794813b.jpg

First Name

Matthew

Last Name

Shaines

NPI

1831270255

Faculty ID

9798

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Dr. Matthew Shaines completed a medical degree at SUNY Downstate Medical Center - Brooklyn and an internal medicine residency at Montefiore/Einstein. He was then recruited to the Einstein faculty at Montefiore and became one of the initial group of hospitalists who founded the Teaching Hospitalist Program at Montefiore in 2004.</p>
<p>Dr. Shaines has served as Assistant Director of the Hospitalist Service, managing the Moses Teaching Hospitalist Program; founding Director of the Medicine Consult Service, creating a dedicated medicine consult rotation for the housestaff, with a mission of high quality service and education on topics pertaining to consultative and perioperative medicine; Associate Program Director for the Internal Medicine Residency Program, serving as a liaison between the program and the Division of Hospital Medicine. In 2018 he was appointed as the Associate Chief of Hospital Medicine for Education.</p>
<p>His teaching and academic interests are in clinical reasoning, quality improvement and faculty development. He serves as the lead vignette reviewer for Montefiore&rsquo;s annual Division of General Internal Medicine/Division of Hospital Medicine SGIM/SHM scholarly review process, which helps to review and critique abstracts, posters and oral presentations prior to submission.</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

4378

Is Open Scheduling

Off

Alexander I. Sankin

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/6a135040-3a87-11ed-8158-59ecbd24247c.jpg

First Name

Alexander

Last Name

Sankin

NPI

1982866570

Faculty ID

14891

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Dr. Sankin is an academic surgeon in the Department of Urology, at Montefiore Medical Center with a clinical focus on surgical approaches to the management of urologic malignancies of the upper urinary tract and bladder. His academic focus is divided between clinical and translational research studying emerging treatments and techniques central to the surgical care of patients with urologic cancers.&nbsp;</p>
<p>Dr. Sankin is the site-Principal Investigator for multiple clinical trials studying novel therapeutics for patients with bladder cancer who wish to avoid radical cystectomy. As an active member of multiple clinical trial consortiums including Eastern Cooperative Oncology Group and the Society of Urologic Oncology Clinical Trials Consortium, Dr. Sankin speardeaded the development of a bladder cancer clinical trials program at Einstein.&nbsp;</p>
<p>His translational research focuses on characterizing the tumor immune microenvironment of bladder tumors and the role of novel checkpoint molecules as relevant therpeutic targets. &nbsp;</p>
<p>&nbsp;</p>

Research Areas

Expert Tags

Areas of Expertise

Expert Summary

<p>Dr. Sankin current research program focuses on the translational application of immune-oncology to the treatment of urologic cancer.</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Dr. Sankin's&nbsp;clinical specialty is surgical approaches to treating urological malignancies, including prostate, testicular, renal and bladder cancer.<quillbot-extension-portal></quillbot-extension-portal>

Research Focus

Building on his clinical focus, Dr. Sankin&rsquo;s research centers on bladder-preserving treatment options in patients with high-risk bladder cancer and the development of new immunotherapies for bladder cancer.&nbsp;<quillbot-extension-portal></quillbot-extension-portal>

Elsevier Profile

Selected Publications

<p align="left">Clark TW,&nbsp;Sankin A, Becske T, Nelson PK, Fox M.&nbsp;&nbsp;Stent-assisted Gugliemi detachable coil repair of wide-necked renal artery aneurysm using 3-D angiography.&nbsp;&nbsp;Vasc Endovascular Surg 2008 Jan; 41(6):528-32</p>
<p align="left">Tareen B,&nbsp;Sankin A, Godoy G, Temkin S, Lepor H, Taneja SS.&nbsp;Appropriate candidates for hemiablative focal therapy are infrequently encountered among men selected for radical prostatectomy in contemporary cohort<em>.</em>&nbsp;Urology.&nbsp;&nbsp;2009 Feb;73(2):351-4</p>
<p align="left">Tareen B, Godoy G,&nbsp;Sankin A, Temkin S, Lepor H, Taneja SS.&nbsp;&nbsp;Laterality alone should not drive selection of candidates for hemi-ablative focal therapy.&nbsp;J Urol.&nbsp;&nbsp;2009 Mar;181(3):1082-9</p>
<p align="left">Tareen B, Godoy G,&nbsp;Sankin A, Temkin S, Lepor H, Taneja SS.&nbsp;&nbsp;Can contemporary transrectal prostate biopsy accurately select candidates for hemi-ablative focal therapy of prostate cancer?&nbsp;&nbsp;BJU Int. 2009 Jul;104(2):195-9</p>
<p align="left">Marien T,&nbsp;Sankin A, Lepor H.&nbsp;&nbsp;Factors predicting preservation of erectile function in men undergoing open radical retropubic prostatectomy.&nbsp;&nbsp;J Urol.&nbsp;&nbsp;2009 Apr;181(4):1817-22</p>
<p align="left">Sankin A, Tareen B, Lepor H.&nbsp;&nbsp;Side-specific factors associated with extracapsular extension and seminal vesicular invasion in men undergoing open radical retropubic prostatectomy.&nbsp;&nbsp;Prostate Cancer Prostatic Dis.&nbsp;&nbsp;2009;12(2):204-8</p>
<p align="left">Mufarrij P,&nbsp;Sankin A, Godoy G, Lepor H.&nbsp;Pathologic outcomes of candidates for active surveillance undergoing radical prostatectomy.&nbsp;&nbsp;Urology.&nbsp;&nbsp;2010 Sep;76(3):689-92</p>
<p align="left">Sankin A, Cohen J, Wang H, Macchia RJ, Karanikolas N.&nbsp;&nbsp;Rate of renal cell carcinoma subtypes in different races.&nbsp;&nbsp;Int Braz J Urol.&nbsp;&nbsp;2011 Feb;37(1):29-32</p>
<p align="left">Sankin A, Sfakianos J, Schiff J, Sjoberg D, Coleman J.&nbsp;Assessing renal function following partial nephrectomy using renal nuclear scintigraphy and eGFR.&nbsp;&nbsp;Urology.&nbsp;&nbsp;2012 Aug;80(2):343-6</p>
<p align="left">Ghavamian R, Hakimi AA, Williams SK, Kim PH, Chen L, Sfakianos JP, Keren-Paz GE,&nbsp;Sankin A,&nbsp;Ginzburg N, Coleman JA.&nbsp;&nbsp;Factors affecting proportional glomerular filtration rate following minimally invasive partial nephrectomy.&nbsp;&nbsp;J Endourology&nbsp;&nbsp;2013 Nov;27(11):1371-5</p>
<p align="left">Sankin A, Hakimi AA, Mikkilineni N, Ostrovnaya I, Silk MT, Liang Y, Mano R, Chevinsky M, Motzer RJ, Solomon SB, Cheng EH, Durack JC, Coleman JA, Russo P, Hsieh JJ.&nbsp;&nbsp;The impact of genetic heterogeneity on biomarker development in kidney cancer assessed by multiregional sampling.&nbsp;&nbsp;Cancer Medicine 2014 Dec;3(6):1485-92</p>
<p align="left">Mano R, Vertosick E,&nbsp;Sankin A,&nbsp;Chevinsky M, Larish Y, Jakubowski CD, Hotker AM, Sjoberg D, Akin O, Russo P.&nbsp;&nbsp;The clinical significance of indeterminate pulmonary nodules in patients with renal cell carcinoma.&nbsp;&nbsp;J Urol 2014 Mar;193(3):776-82</p>
<p align="left">Chevinsky M, Imnadze M,&nbsp;Sankin A, Winer A, Mano R, Jakubowski C, Mashni J, Sjoberg DD, Chen YB, Tickoo SK, Reuter VE, Hakimi AA, Russo P.&nbsp;Pathologic stage T3a significantly increases disease recurrence across all tumor sizes in renal cell carcinoma.&nbsp;J Urol 2015 Aug;194(2):310-5</p>
<p align="left">Hakimi AA, Tickoo S, Jacobsen A, Sarungbam J, Sfakianos J, Sato Y, Morikawa T, Kume H, Fukayama M, Homma Y, Chen YB,&nbsp;Sankin A,&nbsp;Mano R, Coleman JA, Russo P, Ogawa S, Sander C, Hsieh JJ, Reuter VE.&nbsp;TCEB1-mutated renal cell carcinoma: a distinct genomic and morphologic subtype.&nbsp;&nbsp;Mod Pathol 2015 June;28(6):845-53</p>
<p align="left">Sankin A,&nbsp;Hakimi AA, Hsieh JJ, Molina AM.&nbsp;&nbsp;Metastatic non-clear cell renal cell carcinoma: an evidence based review of current treatment strategies.&nbsp;&nbsp;Front Oncol 2015 Apr 8;5:67</p>
<p align="left">Hakimi AA, Ostrovnaya I, Jacobsen A, Susztak K, Coleman JA, Russo P, Winer AG, Mano R,&nbsp;Sankin A, Motzer RJ, Voss MH, Offit K, Purdue M, Pomerantz M, Freedman M, Choueiri TK, Hsieh JJ, Klein RJ.&nbsp;&nbsp;Validation and genomic interrogation of the MET variant rs11762213 as a predictor of adverse outcomes in clear cell renal cell&nbsp;carcinoma.&nbsp;&nbsp;Cancer 2016 Feb 1;122(3):402-10</p>
<p align="left">Sankin A. Discovering biomarkers within the genomic landscape of renal cell carcinoma.&nbsp;&nbsp;J Kidney 2016 Feb 2(1)&nbsp;</p>
<p align="left">Sankin A, Tin A, Mano R, Chevinsky M, Jakubowski C, Cha E, Yee A, Friedman F, Sjoberg D, Ehdaie B, Coleman J.&nbsp;&nbsp;Impact of ureteroscopy prior to nephroureterectomy for upper tract urothelial carcinoma on oncologic outcomes.&nbsp;&nbsp;Urology 2016 Aug; 94:148-53</p>
<p align="left">Mano R, Hakimi AA,&nbsp;Sankin AI,&nbsp;Sternberg IA, Chevinsky MS, Russo P.&nbsp;&nbsp;Surgical treatment of tumors involving kidneys with fusion anomalies &ndash; a contemporary series.&nbsp;&nbsp;Urology 2016 Aug; 98:97-102</p>
<p align="left">Zhou TC,&nbsp;Sankin A,&nbsp;Porcelli SA, Perlin DS, Schoenberg MP, Zang XX.&nbsp;&nbsp;A review of the PD-1/PD-L1 checkpoint in bladder cancer: from mediator of immune escape, to target for treatment.&nbsp;&nbsp;Urol Oncol 2017 Jan;35(1):14-20&nbsp;</p>
<p align="left">Winer AG, Vertosick EA, Ghanaat M, Corradi RB, Carlsson S, Sjoberg DD,&nbsp;Sankin AI,&nbsp;Sfakianos JP, Cha EK, Dalbagni G, Coleman JA.&nbsp;Prognostic value of lymph node yield during nephroureterectomy for upper tract urothelial carcinoma.&nbsp;&nbsp;Urol Oncol 2017 April;35(4):151</p>
<p align="left">Sankin&nbsp;A,&nbsp;Narasimhulu&nbsp;D, John P,&nbsp;Gartrell&nbsp;B, Schoenberg M, Zang XX.&nbsp; The expanding repertoire of targets for immune checkpoint inhibition in bladder cancer: what lies beneath the tip of the iceberg, PD-L1.&nbsp;&nbsp;Urol&nbsp;Onc&nbsp;2017 (Epub ahead of print)</p>
<p align="left">Milbar N, Kates M, Chappidi MR, Pederzoli F, Yoshida T,&nbsp;Sankin A,&nbsp;Pierorazio PM, Schoenberg MP, Bivalacqua TJ. Oncological outcomes of sequential intravesical gemcitabine and docetaxel in patients with non-muscle invasive bladder cancer.&nbsp;&nbsp;Bladder Cancer 2017 Oct 27;3(4):293-303</p>
<p align="left">Daneshmand S, Patel s, Lotan Y, Pohar K, Trabulsi E, Woods M, Downs T, Huang W, Jones J, O&rsquo;Donnell M, Bivalacqua T, DeCastro J, Steinberg G, Kamat A, Resnick M, Konety B, Schoenberg M, Jones JS,&nbsp;Flexible Blue Light Study Group Collaborators.&nbsp;Efficacy and Safety of Blue Light Flexible Cystoscopy with Hexaminolevulinate in the Surveillance of Bladder Cancer: A Phase III, Comparative, Multicenter Study.&nbsp;&nbsp;J Urol 2018 May;199(5):1158-65</p>
<p align="left">Fridman D, Abeshouse M,&nbsp;Sankin A.&nbsp;Paraurethral Leiomyoma as an Incidental Finding in a Patient with Fibroid Uterus. Case Rep Obstet Gynecol 2018 Feb 7;2018</p>
<p align="left">Adrianzen Hererra DA, Goldberg-Stein S,&nbsp;Sankin A, Sarungbam J, Sharma J, Gartrell BA. Synchronous Bone Metastasis From Multiple Myeloma and Prostate Adenocarcinoma as Initial Presentation of Coexistent Malignancies. Front Oncol, 2018 Apr 30;8:137</p>
<p align="left">Berstein A, Fram EB,&nbsp;Sankin A, Kovac E, Srivastava A, DiVito J, Stern JM. A Comparison of Perinephric Fat Surface Area and Mayo Adhesive Probability Score in Predicting Malignancy in T1 Renal Masses.&nbsp;&nbsp;Urol Onc 2018 Nov; 36(11):499</p>
<p align="left">Sun Y, Reuter VE, Magi-Galluzzi C,&nbsp;Sankin A,&nbsp;Epstein JI.&nbsp;Granular Cell Tumor of the Bladder: A Report of Six Cases.&nbsp;&nbsp;Urology 2018 Nov; 121:203&nbsp;</p>
<p align="left">Leow JJ, Bedke J, Chamie K, Collins JW, Daneshmand S, Grivas P, Heidenreich A, Messing EM, Royce TJ,&nbsp;Sankin A,&nbsp;Schoenberg MP, Shipley WU, Villers A, Efstathiou J, Bellmunt J, Stenzl A.&nbsp;&nbsp;Recommendations From Joint SIU-ICUD Consultation On Bladder Cancer: Muscle-Invasive Presumably Regional Tumor.&nbsp;&nbsp;World J Urol 2019, Jan;37(1): 61-83</p>
<p align="left">Chand D, Dhawan D,&nbsp;Sankin A, Ren X, Lin J, Schoenberg M, Knapp DW, Zang X. Immune checkpoint B7x (B7-H4/B7S1/VtCN1) is overexpressed in spontaneous canine bladder cancer: the first report and its implications in a preclinical model. Bladder Cancer 2019, Jan 31;5(1)63-71</p>
<p align="left">Bernstein A, Barry E, Fram EB,&nbsp;Sankin A,&nbsp;Kovac E, Stern JM.&nbsp;Does Glomerular Filtration Rate at Discharge After Partial Nephrectomy Predict Long-Term Glomwerular Filtration Rate Stability?. J Endourol 2019, Jun;33(6):488-491</p>
<p align="left">Lotan Y, Bivalacqua TJ, Downs T, Huang W, Jones J, Kamat A, Konety B, Malmstrom PU, McKiernan J, O&rsquo;Donnell M, Patel S, Pohar K, Resnick M,&nbsp;Sankin A,&nbsp;Smith A, Steinberg G, Trabulsi E, Woods M, Daneshmand S.&nbsp;&nbsp;Blue light flexible cystoscopy with hexaminolevulinate in non-muscle invasive bladder cancer: review of the clinical evidence and consensus statement on optimal use in the USA &ndash; update 2018. Nat Rev Urol 2019, Jun;16(6):377-386</p>
<p align="left">Sankin A,&nbsp;Chand D, Schoenberg M, Zang X.&nbsp;&nbsp;Human urothelial bladder cancer generates a clonal immune response: the results of T-cell receptor sequencing.&nbsp;&nbsp;Urol Oncol 2019, May 15 (epub ahead of print).</p>
<p align="left">Wang H, Kaur G,&nbsp;Sankin A,&nbsp;Chen F, Guan F, Zang X.&nbsp;Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies.&nbsp;&nbsp;J Hematol Oncol 2019, Jun 11;12(1):59</p>
<p align="left">Daniels MJ, Barry E, Schoenberg M, Lamm DL, Bivalacqua TJ,&nbsp;Sankin A, Kates M.&nbsp;&nbsp;Contemporary oncologic outcomes of second induction course BCG in patients with nonmuscle invasive bladder cancer. Urol Oncol 2019, Jun 26 (epub ahead of print)</p>
<p align="left">Daniels MJ, Barry E, Milbar N, Schoenberg M, Bivalacqua TJ,&nbsp;Sankin A, Kates M. An evaluation of monthly maintenance therapy among patients receiving intravesical combination gemcitabine/docetaxel for nonmuscle invasive bladder cancer.&nbsp;&nbsp;Urol Oncol 2019, Aug 28 (epub ahead of print)</p>
<p align="left">Khaki AR, Li A, Diamantopoulos LN, Bilen MA, Santos V, Esther J, Morales-Barrera R, Devitt M, Nelson A, Holmes CJ, Shreck E, Assi H, Gartrell BA, Sankin A,&nbsp;Rodriguez-Vida A, Lythgoe M, Pinato DJ, Drakaki A, Joshi M, Isaacsson Velho P, Hahn N, Liu S, Alonso Buznego L, Duran I, Moses M, Jain J, Murgic J, Baratam P, Barata P, Tripathi A, Zakharia Y, Galsky MD, Sonpavde G, Yu EY, Shankaran V, Lyman GH, Grivas P.&nbsp;&nbsp;Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with checkpoint inhibitors.&nbsp;&nbsp;Cancer 2019, Dec 12 (epub ahead of print)</p>

EMR ID

78143

Biography

<p>Alexander I. Sankin, MD, is Associate Professor, Urology at Montefiore Einstein. His clinical specialty is surgical approaches to treating urological malignancies, including prostate, testicular, renal and bladder cancer.</p><p>After earning his Master of Science from the University of Pennsylvania in 2004, Dr. Sankin earned his Doctor of Medicine from New York University in 2008 and completed his residency in surgery and urology at the State University of New York Downstate in 2013. He then completed a fellowship in urologic oncology at Memorial Sloan Kettering Cancer Center in 2015.</p><p>Building on his clinical focus, Dr. Sankin&rsquo;s research centers on bladder-preserving treatment options in patients with high-risk bladder cancer and the development of new immunotherapies for bladder cancer. He is the site-principal investigator for multiple clinical trials studying novel therapeutics for patients with bladder cancer who wish to avoid radical cystectomy. As an active member of multiple clinical trial consortiums, including Eastern Cooperative Oncology Group and the Society of Urologic Oncology Clinical Trials Consortium, Dr. Sankin spearheaded the development of a bladder cancer clinical trials program at Einstein. His translational research focuses on characterizing the tumor immune microenvironment of bladder tumors and the role of novel checkpoint molecules as relevant therapeutic targets. His work has been published in numerous peer-reviewed journals.</p><p>Dr. Sankin is board certified and a member of the American Urological Association and the Society of Urologic Oncology.</p>

Is Open Scheduling

Off

Michael J. Ross

https://assets.montefioreeinstein.org/profiles/images/physphoto/Ross_Michael_MD_420x504.jpg

First Name

Michael

Last Name

Ross

NPI

1851321368

Faculty ID

15329

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p class="p1">&nbsp;</p>
<p class="p1">The major focus of research in the Ross laboratory is to identify novel mechanisms of kidney injury occurring in HIV-positive persons and his laboratory uses in vitro and murine models to generate new strategies to prevent and treat kidney diseases. Dr. Ross also works with members of the International Network for Strategic Initiatives in Global HIV Treatment (INSIGHT) to perform research on kidney disease in the context of large international HIV treatment trials.</p>
<p class="p1"><strong><span style="text-decoration: underline;">Ongoing NIH-funded projects:</span></strong></p>
<p class="p1"><strong>Mechanisms by which antiretroviral medications protect kidneys from HIV-induced injury:</strong></p>
<p class="p1">Though combination antiretroviral therapy (cART) is efficacious in preventing and treating HIV-associated nephropathy (HIVAN), the mechanisms by which these medications protect the kidney from the deleterious effects of HIV are poorly understood.&nbsp;&nbsp;We are performing studies using transgenic animal models and molecular and genomic techniques to identify novel pathways by which ART protect the kidneys from HIV.&nbsp;&nbsp;Moreover, we have exciting data suggesting that these medications may protect kidneys from non-viral mediated forms of kidney injury, including diabetic kidney disease.</p>
<p class="p1"><strong>The role of APOL1 polymorphisms in promoting HIV-induced kidney injury:</strong></p>
<p class="p1">Polymorphisms in the APOL1 gene account for most of the excess risk of African-Americans to non-diabetic kidney disease and HIV-associated kidney disease in particular. In our studies, we are using genetically modified human kidney cells to perform innovative proteomic, and genomic studies to identify novel mechanisms by APOL1 genetic variants predispose to HIV-induced kidney injury.&nbsp;</p>

Research Areas

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

<p><span style="color:black;">Chronic kidney disease, diabetic kidney disease, acute kidney injury, glomerular diseases, cystic kidney diseases, electrolyte disorders, hypertension, HIV and other virus-related kidney diseases.</span></p>

Research Focus

<p><span style="color:black;">The primary focus of Dr. Ross' research is to identify mechanisms by which HIV and immune dysregulation cause kidney disease and to identify new approaches to prevent and treat kidney disease. Dr. Ross is also involved in clinical studies to determine mechanisms of diabetic kidney injury and to test the effectiveness of novel treatments for chronic kidney diseases.</span></p>

Elsevier Profile

Selected Publications

<p><span style="text-decoration: underline;"><strong>Most relevant publicatiion in past 10 years:</strong></span></p>
<p>*Mocroft, A., Wyatt, C., Szczech, L., Neuhaus, J., El-Sadr, W., Tracy, R., Kuller, L., Shlipak, M., Angus, B., Klinker, H., and <strong><span style="text-decoration: underline;">Ross, MJ</span></strong>. Interruption of antiretroviral therapy is associated with increased plasma cystatin C: Results from the SMART Study. <em>AIDS</em>. 23, 71-82. 2009.</p>
<p>*Snyder A, Alsauskas Z, Gong P, Rosenstiel P, Klotman M, Klotman P, <strong><span style="text-decoration: underline;">Ross MJ</span></strong>: FAT10: a novel mediator of Vpr-induced apoptosis in HIV-associated nephropathy. <em>J Virol</em>. 83;11983-11988. 2009.</p>
<p>*Gong, P., Canaan, A., Wang, B., Leventhal, S., Snyder, A., Nair, V., Cohen, C. D., Kretzler, M., D'Agati, V., Weissman, S., and <strong><span style="text-decoration: underline;">Ross, M. J</span></strong>. The ubiquitin-like protein FAT10 mediates NF-kappaB activation. J Am Soc Nephrol. 21:316. 2009.</p>
<p>Snyder A, Alsauskas ZC, Leventhal JS, Rosenstiel PE, Gong P, Chan J, Barley K, He C, Klotman M, <strong><span style="text-decoration: underline;">Ross MJ</span></strong>, Klotman PE. HIV-1 viral protein r induces ERK and caspase-8 dependent apoptosis in renal tubular epithelial cells. <em>AIDS</em>, 24:1107-1119. 2010.</p>
<p>Neuhaus, J., Jacobs, D.R., Baker, J.V., Calmy, A., Duprez, D., La Rosa, A., Kuller, L., Pett, S.L., Ristola, M., <strong><span style="text-decoration: underline;">Ross, M.J.</span></strong>, Shlipak, M., Tracy, R., and Neaton, J.D. Markers of Inflammation, Coagulation and Renal Function Are Elevated in Adults with HIV Infection. <em>J Infect Dis</em>. 201:1788-1795. 2010.</p>
<p>Chen, P., Chen, B.K., Mosoian, A., Hays, T., <strong><span style="text-decoration: underline;">Ross, M.J</span></strong>., Klotman, P.E., and Klotman, M.E. Virological Synapses Allow HIV-1 Uptake and Gene Expression in Renal Tubular Epithelial Cells. J Am Soc Nephrol. &nbsp;22(3): 496-507. 2011.</p>
<p>Leventhal, J.S., Alsauskas, Z., Snyder, A., Gong, P., Wang, B., D&rsquo;Agati, V., and <strong><span style="text-decoration: underline;">Ross, M.J.</span></strong> Renal HIV Expression Is Unaffected by Serum LPS Levels in an HIV Transgenic Mouse Model of LPS Induced Kidney Injury. <em>PLoS One.</em> <strong>6</strong>:e20688. 2011.</p>
<p>Papeta, N., Kiryluk, K., Patel, A., Sterken, R., Kacak, N., Snyder, H.J., Imus, P.H., Mhatre, A.N., Lawani, A.K., Julian, B.A., Wyatt, R.J., Novak, J., Wyatt, C.M., <strong><span style="text-decoration: underline;">Ross, M.J.</span></strong>, Winston, J.A., Klotman, M.E., Cohen, D.J., Appel, G.B., D&rsquo;Agati, V.D., Klotman, P.E., and Gharavi, A.G. APOL1 variants increase risk for FSGS and HIVAN but not IgA nephropathy. <em>J Am Soc Nephrol.</em> 22:1991-1996. 2011.</p>
<p>Mocroft A, Neuhaus J, Peters L, Ryom L, Bickel M, Grint D, Koirala J, Szymczak A, Lundgren J, <strong><span style="text-decoration: underline;">Ross MJ</span></strong>*, Wyatt CM*: Hepatitis B and C Co-Infection Are Independent Predictors of Progressive Kidney Disease in HIV-Positive, Antiretroviral-Treated Adults. PLoS ONE 7:e40245, (*co-senior authors). 2012.</p>
<p>Ryom L, Mocroft A, Kirk O, Worm SW, Kamara DA, Reiss P, <strong><span style="text-decoration: underline;">Ross M</span></strong>, Fux CA, Morlat P, Moranne O, Smith C, Lundgren JD: Exposure to Antiretrovirals (ARVs) and Risk of Renal Impairment among HIV-positive Persons with Normal Baseline Renal Function: the D:A:D study. J Infect Dis 2013.</p>
<p>Ganesan A, Krantz EM, Huppler Hullsiek K, Riddle MS, Weintrob AC, Lalani T, Okulicz JF, Landrum M, Agan B, Whitman TJ, <strong><span style="text-decoration: underline;">Ross MJ</span></strong>, Crum-Cianflone NF: Determinants of incident chronic kidney disease and progression in a cohort of HIV-infected persons with unrestricted access to health care. HIV Med 14:65-76, 2013</p>
<p>Ryom L, Mocroft A, Kirk O, Worm SW, Kamara DA, Reiss P, <strong><span style="text-decoration: underline;">Ross M</span></strong>, Fux CA, Morlat P, Moranne O, Smith C, Lundgren JD; D:A:D Study Group. Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study. J Infect Dis. 1;207(9):1359-69. 2013.</p>
<p>Lucas, G., Cozzi-Lepri, A., Wyatt, C., Post, F., Bormann, A., Crum-Cianflone, N., and <strong><span style="text-decoration: underline;">Ross, M</span></strong>. Glomerular filtration rate estimated using creatinine, cystatin C or both markers and the risk of clinical events in HIV-infected individuals. HIV Med 15:116-123. PubMed PMID: 24024499. 2014.</p>
<p>Lucas, GM, <strong><span style="text-decoration: underline;">Ross, MJ</span></strong>, Stock, PG, Shlipak, MG, Wyatt, CM, Gupta, SK, Atta, MG, Wools-Kaloustian, KK, Pham, PA, Bruggeman, LA, Lennox, JL, Ray, PE, and Kalayjian, RC. Clinical Practice Guideline for the Management of Chronic Kidney Disease in Patients Infected With HIV: 2014 Update By the HIV Medicine Association of the Infectious Diseases Society of America. <em>Clin Infect Dis</em>; 59(9), e96-e138. 2014.</p>
<p>Ryom, L., Mocroft, A., Kirk, O., <strong><span style="text-decoration: underline;">Ross, M</span></strong>., Reiss, P., Fux, C. A., Morlat, P., Moranne, O., Smith, C., El-Sadr, W., Law, M., and Lundgren, J. D. Predictors of advanced chronic kidney disease and end-stage renal disease in HIV-positive persons. AIDS 28, 187-199. 2014.</p>
<p>Mocroft A, Lundgren J, <strong><span style="text-decoration: underline;">Ross M</span></strong>, Law M, Reiss P, Kirk O, Smith C, Wentworth D, Heuhaus J, Fux C, Moranne O, Morlat P, Johnson M, Ryom L; Data on Adverse Events&nbsp; (D:A:D) study group, the Royal Free Hospital Clinic Cohort and the INSIGHT study&nbsp; group. A clinically useful risk-score for chronic kidney disease in HIV infection. J Int AIDS Soc ;17(4 Suppl 3):19514.. PMID: 25394023; PMCID: PMC4224906. 2014.</p>
<p>Leventhal, J.S., He, J.C., and <strong><span style="text-decoration: underline;">Ross, M.J</span></strong><span style="text-decoration: underline;">.</span> Autophagy and Immune Response in Kidneys. <em>Semin Nephrol.</em> 34(1):53-61. 2014.</p>
<p><strong><span style="text-decoration: underline;">Ross, M. J.</span></strong> (2014). Advances in the pathogenesis of HIV-associated kidney diseases. <em>Kidney Int.</em> 86, 266-274. 2014.</p>
<p>Mocroft A, Lundgren JD, <strong><span style="text-decoration: underline;">Ross M</span></strong>, Law M, Reiss P, Kirk O, Smith C, Wentworth D, Neuhaus J, Fux CA, Moranne O, Morlat P, Johnson MA, Ryom L; D:A:D study group; Royal Free Hospital Clinic Cohort; INSIGHT study group; SMART study group; ESPRIT study group. Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study. PLoS Med. 2015 Mar 31;12(3):e1001809. PMID: 25826420; PMCID: PMC4380415. 2015.</p>
<p>Wolf T, <strong><span style="text-decoration: underline;">Ross MJ*</span></strong>, and Davenport A. Minimizing risks associated with renal replacement therapy in patients with Ebola Virus Disease. <em>Kidney Int.</em> 2015. 87, 5-7. 2015.</p>
<p>Achhra AC, Mocroft A, <strong><span style="text-decoration: underline;">Ross MJ</span></strong>, Ryom L, Lucas GM, Furrer H, Neuhaus J, Somboonwit C, Kelly M, Gatell JM, Wyatt CM; International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) START Study Group. Kidney disease in antiretroviral-na&iuml;ve HIV-positive adults with high CD4 counts: prevalence and predictors of kidney disease at enrolment in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med;16 Suppl 1:55-63. PMID: 25711324; PMCID: PMC4341947. 2015.</p>
<p>Mocroft A, Lundgren JD, <strong><span style="text-decoration: underline;">Ross M</span></strong>, Fux CA, Reiss P, Moranne O, Morlat P, Monforte Ad, Kirk O, Ryom L; Data Collection on Adverse events of Anti-HIV Drugs (D:A:D) Study. Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study. Lancet HIV. 3:e23-32. 2016.</p>
<p>Leventhal JS, Ni J, Osmond M, Lee K, Gusella GL, Salem F, <strong><span style="text-decoration: underline;">Ross MJ</span></strong>. Autophagy Limits Endotoxemic Acute Kidney Injury and Alters Renal Tubular Epithelial Cell Cytokine Expression. PLoS One. 11(3):e0150001. 2016.</p>
<p>Ryom, L, Lundgren, JD, <strong><span style="text-decoration: underline;">Ross, M</span></strong>, Kirk, O, Law, M, Morlat, P, Smit, C, Fontas, E, Fux, CA, Hatleberg, CI, de Wit, S, Sabin, CA, Mocroft, A, D:A:D, SG. Renal Impairment and Cardiovascular Disease in HIV-positive Individuals; The D:A:D Study. J Infect Dis. PMID: 27485357. 2016.</p>
<p>Ryom L, Mocroft A, Kirk O, Reiss P, <strong><span style="text-decoration: underline;">Ross M,</span></strong> Smith C, Moranne O, Morlat P, Fux CA, Sabin C, Phillips A, Law M, Lundgren JD; D:A:D study group.. Predictors of eGFR progression, stabilisation or improvement after chronic renal impairment in HIV-positive individuals. AIDS. 2017 Mar 28. PMID: 28353536.</p>
<p>Nadkarni GN, Wyatt CM, Murphy B, <strong><span style="text-decoration: underline;">Ross MJ</span></strong>. APOL1: a case in point for replacing race with genetics. Kidney Int. 2017 Apr;91(4):768-770. PMID: 28314574.</p>
<p>Rednor SJ, <strong>Ross MJ</strong>. Molecular Mechanisms of Injury in HIV-Associated Nephropathy. Front Med (Lausanne). 2018; 5:177. PMID: 29930940 PMCID: PMC5999756</p>
<p><strong><span style="text-decoration: underline;">Ross MJ</span></strong>, Coates PT. Using CRISPR to inactivate endogenous retroviruses in pigs: an important step toward safe xenotransplantation. Kidney Int. 2018; 93:4-6, PMID: 29198467.</p>
<p><strong><span style="text-decoration: underline;">Ross MJ.</span></strong> New Insights into APOL1 and Kidney Disease in African Children and Brazilians Living With End-Stage Kidney Disease. Kidney Int Rep. 2019; 4:908-910 PMC6611947.</p>
<p>Ryom L, Dilling Lundgren J, Reiss P, Kirk O, Law M, <strong><span style="text-decoration: underline;">Ross M</span></strong>, Morlat P, Andreas Fux C, Fontas E, De Wit S, D'Arminio Monforte A, El-Sadr W, Phillips A, Ingrid Hatleberg C, Sabin C, Mocroft A. Use of Contemporary Protease Inhibitors and Risk of Incident Chronic Kidney Disease in Persons With Human Immunodeficiency Virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study. J Infect Dis. 2019 Oct 8;220(10):1629-1634. doi: 10.1093/infdis/jiz369. PubMed PMID: 31504669; PubMed Central PMCID: PMC6782100.</p>
<p>Gao X, Rosales A, Karttunen H, Bommana GM, Tandoh B, Yi Z, Habib Z, Agati V, Zhang W, <strong><span style="text-decoration: underline;">Ross MJ</span></strong>. The HIV protease inhibitor darunavir prevents kidney injury via HIV-independent mechanisms. Sci Rep. 2019 Nov 1;9(1):15857. doi: 10.1038/s41598-019-52278-3. PubMed PMID: 31676833; PubMed Central PMCID: PMC6825220.</p>
<p>Townsend RR, Guarnieri P, Argyropoulos C, Blady S, Boustany-Kari CM, Devalaraja-Narashimha K, Morton L, Mottl AK, Patel U, Palmer M, <strong><span style="text-decoration: underline;">Ross MJ</span></strong>, Sarov-Blat L, Steinbugler K, Susztak K. Rationale and design of the Transformative Research in Diabetic Nephropathy (TRIDENT) Study. Kidney Int. 2020 Jan;97(1):10-13. doi: 10.1016/j.kint.2019.09.020. PubMed PMID: 31901339.</p>
<div class="citation-text" data-citation-style="ama">Akalin E, Azzi Y, Bartash R, Seethamraju H, Parides M, Hemmige V, <strong><span style="text-decoration: underline;">Ross M,</span></strong> Forest S, Goldstein YD, Ajaimy M, Liriano-Ward L, Pynadath C, Loarte-Campos P, Nandigam PB, Graham J, Le M, Rocca J, Kinkhabwala M. Covid-19 and Kidney Transplantation. N Engl J Med. 2020 Jun 18;382(25):2475-2477. doi: 10.1056/NEJMc2011117. Epub 2020 Apr 24. PMID: 32329975; PMCID: PMC7200055.</div>

EMR ID

1540

Biography

<p>Dr. Michael Ross received his MD degree at NYU and completed internal medicine residency training at Duke University, followed by Nephrology Fellowship training at the Icahn School of Medicine at Mount Sinai. While he was on the faculty in the Mount Sinai Division of Nephrology from 2001-17, he served as Nephrology Fellowship Program Director from 2004-2015. He became Chief of Nephrology at the James J. Peters VA Medical Center from 2014-2017, where he helped establish the only VA Kidney Transplant Program in the northeastern US. Dr. Ross became Chief of the Division of Nephrology at the Albert Einstein College of Medicine/Montefiore Medical Center in 2017 where he is currently Chief of Nephrology and Professor of Medicine and Developmental and Molecular Biology.&nbsp;</p><p>Dr. Ross has served in several national/international leadership roles for the American Society of Nephrology and other organizations, served as Deputy Editor of Kidney International, and is currently Nephrology Section Editor of the American College of Physicians Medical Knowledge and Self-Assessment Program. Dr. Ross was also the recipient of the 2021 American Society of Nephrology Distinguished Leader Award. The major focus of Dr. Ross&rsquo; research program is to identify novel mechanisms of HIV-induced kidney diseases and other forms of kidney injury. He is also site principal investigator of clinical and translational research studies of diabetic kidney disease and other kidney diseases.&nbsp;<br /></p>

Is Open Scheduling

Off

Norman L. Rosen

https://assets.montefioreeinstein.org/profiles/images/default-profile-blue.svg

First Name

Norman

Last Name

Rosen

NPI

1053492215

Faculty ID

4387

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

3442

Is Open Scheduling

Off

Mark A. Ramirez

https://assets.montefioreeinstein.org/profiles/images/physphoto/Ramirez_Mark_MD.jpg

First Name

Mark

Last Name

Ramirez

NPI

1467494336

Faculty ID

3064

CMO Specialties

Clinical Terms

Employment Status

Per Diem

Patient Type

Adult

Department

Languages

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

3582

Is Open Scheduling

Off

Amanda C. Raff

https://assets.montefioreeinstein.org/profiles/images/amanda-raff.jpg

First Name

Amanda

Last Name

Raff

NPI

1952490369

Faculty ID

8749

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: Cambria; line-height: 15.6pt;">Dr. Raff is a Professor of Medicine and the Associate Chair of Medicine for Undergraduate Medical Education. She has been the Course Director for the Einstein first year medical student Renal System Course since 2007 and the Internal Medicine Clerkship and Acting Internship Director since 2012.</p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: Cambria; line-height: 15.6pt;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: Cambria;">She a faculty mentor for the student led Step 1 Group near-peer evidence based guidance program and the Internal Medicine Interest Group.</p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: Cambria;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: Cambria;">She has a clinical practice of CKD and ESRD patients and enjoys rounding on the inpatient Renal Consult and Dialysis services.</p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: Cambria;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: Cambria;">Dr. Raff&rsquo;s contributions in the field of Medical Education include serving as a Case Editor for&nbsp;&nbsp;Aquifer Internal Medicine, contributing author and reviewer for the Clerkship Directors in Internal Medicine (CDIM) curriculum revision and MKSAP 19 Nephrology section committee member.</p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: Cambria; line-height: 15.6pt;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: Cambria; line-height: 15.6pt;">She has been recognized for her teaching excellence at Einstein with the Samuel M. Rosen Outstanding Teacher Award for Excellence in Basic Science Teaching, the Harry Eagle Award for Outstanding Basic Science Teaching, the Harry H. Gordon Award for Outstanding Clinical Teaching and membership in the Leo M. Davidoff Society.</p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: Cambria; line-height: 15.6pt;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: Cambria; line-height: 15.6pt;">Dr. Raff received a bachelor's degree in biology from Indiana University and a MD from Albert Einstein College of Medicine. She completed a residency in Internal Medicine at NewYork Presbyterian Hospital and a chief resident year at NYU Downtown Hospital. She returned to Einstein/Montefiore for a Nephrology Fellowship and joined the Einstein Division of Nephrology faculty in 2004.</p>

Research Areas

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Autosomal Dominant Polycystic Kidney Disease (ADPKD)<br />Chronic Kidney Disease (CKD)<br />End Stage Kidney Disease (ESKD, ESRD)<br />Acute Kidney Injury (AKI)<br />Glomerular diseases<br />Hypertension<br />Electrolyte Disorders<br />Kidney Stones<br />

Research Focus

<p><span style="color:black;">&nbsp;</span></p>

Elsevier Profile

Selected Publications

<p style="margin-right: 0in; margin-left: 0in; font-size: 10pt; font-family: 'Times New Roman';"><span style="font-size: 12pt; font-family: Cambria;">1.&nbsp;</span><span style="font-size: 12pt; font-family: Cambria; color: #212121;">Fitz M, Adams W, Haist S, Hauer K, Ross P,&nbsp;<strong>Raff A</strong>, Agarwal G, Vu T, Appelbaum J, Lang V, Miller C, Grum C and the Clerkship Directors in Internal Medicine &ndash; National Board of Medical Examiners EXPRESS Study Group. Which Internal Medicine Clerkship Characteristics Are Associated With Students' Performance on the NBME Medicine Subject Exam? A Multi-Institutional Analysis.&nbsp;<em>Acad Med</em>. 2020;10.1097/ACM.0000000000003322 [published online ahead of print, 2020 Mar 17].&nbsp;</span></p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 10pt; font-family: 'Times New Roman';"><span style="font-size: 12pt; font-family: Cambria; color: #212121;">2.&nbsp;</span><span style="font-size: 12pt; font-family: Cambria;">Brien K (Author), Calvo L (Associate editor),&nbsp;<strong>Raff A</strong>&nbsp;(Case editor).&nbsp;<em>Aquifer Internal Medicine Case 33: 49-year-old woman with confusion</em>. 2019&nbsp;</span><u><span style="font-size: 12pt; font-family: Cambria; color: #3366ff;">https://www.aquifer.org</span></u></p&gt;
<p style="margin-right: 0in; margin-left: 0in; font-size: 10pt; font-family: 'Times New Roman';"><span style="font-size: 12pt; font-family: Cambria; color: #212121;">3.&nbsp;</span><span style="font-size: 12pt; font-family: Cambria;">Khan M, Gil N, Lin W, Fiter R, Kenawy D, Burton W,&nbsp;<strong>Raff A</strong>.&nbsp;&nbsp;The impact of Step 1 scores on medical students&rsquo; residency specialty choice.&nbsp;<em>Med Sci Educ.</em>&nbsp;28(4): 699-705. 2018.</span></p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 10pt; font-family: 'Times New Roman';"><span style="font-size: 12pt; font-family: Cambria;">4.&nbsp;Ludwig A,&nbsp;<strong>Raff A</strong>, Lin J, Schoenbaum E. Group Observed Structured Encounter (GOSCE) for third year medical students improves self-assessment of clinical communication.&nbsp;<em>Medical Teacher</em>&nbsp;39(9): 931-5.&nbsp;2017.</span></p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 10pt; font-family: 'Times New Roman';"><span style="font-size: 12pt; font-family: Cambria;">5.&nbsp;Golestaneh L, Neugarten J, Southern W, Kargoli F,&nbsp;<strong>Raff A</strong>.&nbsp;&nbsp;Improving the diagnostic workup of hyponatremia in the setting of kidney disease: a continuing medical education (CME) initiative.&nbsp;<em>Int Urol Nephrol</em>&nbsp;49(3): 491-7. 2017</span></p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 10pt; font-family: 'Times New Roman';"><span style="font-size: 12pt; font-family: Cambria;">6.&nbsp;Czapka M,&nbsp;<strong>Raff A</strong>, Risley M.&nbsp;&nbsp;Safe Transitions: An active learning module for discharge summaries and interprofessional care.&nbsp;<em>MedEdPORTAL&nbsp;iCollaborative</em>. 2017</span></p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 10pt; font-family: 'Times New Roman';"><span style="font-size: 12pt; font-family: Cambria;">7.&nbsp;Tanenbaum, E, Johnson J, Jordan, E, Cottral J, Tenore C, Burton W, McGinn A<strong>, Raff A</strong>.&nbsp;&nbsp;An effective evidence-based student run near-peer support group for the USMLE Step 1 Exam.&nbsp;&nbsp;<em>Med Sci Educ</em>. 26(4): 691-9. 2016</span></p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 10pt; font-family: 'Times New Roman';"><span style="font-size: 12pt; font-family: Cambria;">8.&nbsp;Ludwig A, Lee R, Parish S,&nbsp;<strong>Raff A</strong>. Four-station group observed structured clinical encounter for formative assessment of communication skills for internal medicine clerks.&nbsp;<em>MedEdPORTAL Publications</em>. 12:10444. 2016&nbsp;</span></p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 10pt; font-family: 'Times New Roman';"><span style="font-size: 12pt; font-family: Cambria;">9.&nbsp;Chen W, Melamed M, Hostetter T, Bauer C,&nbsp;<strong>Raff A</strong>, Almudevar A, Lalonde A, Messing S, Abramowitz M.&nbsp;&nbsp;Effect of oral sodium bicarbonate on fibroblast growth factor-23 in patients with chronic kidney disease: a pilot study.&nbsp;&nbsp;<em>BMC Nephrol</em>. 17(1): 114. doi: 10.1186/s12882-016-0331-6. 2016</span></p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 10pt; font-family: 'Times New Roman';"><span style="font-size: 12pt; font-family: Cambria;">10.&nbsp;Jion Y,&nbsp;<strong>Raff A</strong>, Grosberg B, Evans R.&nbsp;&nbsp;The risk and management of kidney stones from the use of topiramate and zonisamide in migraine and idiopathic intracranial hypertension.&nbsp;&nbsp;<em>Headache</em>. 55(1): 161-6. 2015</span></p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 10pt; font-family: 'Times New Roman';"><span style="font-size: 12pt; font-family: Cambria;">11. Jion Y,&nbsp;<strong>Raff A</strong>, Grosberg B, Evans R.&nbsp;&nbsp;Topiramate and nephrolithiasis: a response.&nbsp;&nbsp;<em>Headache</em>. 55(5): 710-2. 2015</span></p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 10pt; font-family: 'Times New Roman';"><span style="font-size: 12pt; font-family: Cambria;">12.&nbsp;Abramowitz, M, Melamed M, Bauer C,&nbsp;<strong>Raff A</strong>, Hostetter T.&nbsp;&nbsp;Effects of oral sodium bicarbonate in patients with CKD.&nbsp;&nbsp;<em>Clin J Am Soc Nephrol</em>. 8(5): 714-20. 2013</span></p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 10pt; font-family: 'Times New Roman';"><span style="font-size: 12pt; font-family: Cambria;">13. Berman N, Lectura M, Thurman J, Reinecke J,&nbsp;<strong>Raff A</strong>, Melamed M, Quan Z, Evans T, Meyer T, Hostetter T.&nbsp;&nbsp;A zebrafish model for uremic toxicity: role of the complement pathway.&nbsp;&nbsp;<em>Blood Purif</em>. 35(4): 265-9. 2013</span></p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 10pt; font-family: 'Times New Roman';"><span style="font-size: 12pt; font-family: Cambria;">14.&nbsp;Bomback A,&nbsp;<strong>Raff A</strong>.&nbsp;&nbsp;Olfactory function in dialysis patients: a potential key to understanding the uremic state.&nbsp;&nbsp;<em>Kidney Int</em>.&nbsp;&nbsp;80(8): 803-5.&nbsp;&nbsp;2011</span></p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 10pt; font-family: 'Times New Roman';"><span style="font-size: 12pt; font-family: Cambria;">15.&nbsp;Ponda M, Quan Z, Melamed M,&nbsp;<strong>Raff A</strong>, Meyer T, Hostetter T.&nbsp;&nbsp;&nbsp;Methylamine clearance by haemodialysis is low.&nbsp;&nbsp;<em>Nephrol Dial Transplant</em>.&nbsp;&nbsp;25(5): 1608-13. 2010</span></p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 10pt; font-family: 'Times New Roman';"><span style="font-size: 12pt; font-family: Cambria;">16.&nbsp;<strong>Raff A</strong>,&nbsp;&nbsp;Lieu S, Melamed M, Quan Z, Ponda M, Meyer T, Hostetter T.&nbsp;&nbsp;Relationship of Impaired Olfactory Function in ESRD to Malnutrition and Retained Uremic Molecules.&nbsp;<em>Am J Kidney Dis</em>.&nbsp;&nbsp;52(1): 102-10.&nbsp;&nbsp;2008</span></p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 10pt; font-family: 'Times New Roman';"><span style="font-size: 12pt; font-family: Cambria;">17.&nbsp;<strong>Raff A</strong>, Meyer T, Hostetter T.&nbsp;&nbsp;New Insights into uremic toxicity.&nbsp;&nbsp;<em>Curr Opin Nephrol Hypertens</em>.&nbsp;&nbsp;17(6): 560-5.&nbsp;&nbsp;2008</span></p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 10pt; font-family: 'Times New Roman';"><span style="font-size: 12pt; font-family: Cambria;">18.&nbsp;Susztak K,&nbsp;<strong>Raff A</strong>, Schiffer M, Bottinger E.&nbsp;&nbsp;Glucose &ndash; induced&nbsp;&nbsp;&nbsp;reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy.&nbsp;<em>Diabetes</em>. 55(1): 225-33.&nbsp;&nbsp;2006</span></p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 10pt; font-family: 'Times New Roman';"><span style="font-size: 12pt; font-family: Cambria;">19.&nbsp;Schiffer M. Susztak K, Ranalletta M,&nbsp;<strong>Raff A</strong>, Bottinger E, Charron M.&nbsp;&nbsp;Localization of the GLUT8 transporter in murine kidney and regulation in vivo in non-diabetic and diabetic conditions.&nbsp;&nbsp;<em>Am J Physiol Renal Physiol</em>, 289(1): F186-193.&nbsp;&nbsp;2005</span></p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 10pt; font-family: 'Times New Roman';"><span style="font-size: 12pt; font-family: Cambria;">20.&nbsp;<strong>Raff A</strong>, Hebert T, Pullman J, Coco M.&nbsp;&nbsp;Crescentic post-streptococcal glomerulonephritis with nephrotic syndrome in the adult: is aggressive therapy warranted?&nbsp;&nbsp;<em>Clinical Nephrology</em>, 63(5): 375-380.&nbsp;&nbsp;2005</span></p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 10pt; font-family: 'Times New Roman';"><span style="font-size: 12pt; font-family: Cambria;">21.&nbsp;Spector M,&nbsp;<strong>Raff A</strong>, DeSilva H, Lee K, Osley M.&nbsp;&nbsp;Hir1p and Hir2p function as transcriptional corepressors to regulate histone gene transcription in&nbsp;<em>Saccharomyces cerevisiae&nbsp;</em>cell cycle.&nbsp;<em>&nbsp;Molecular and Cellular Biology</em>, 17(2):&nbsp;&nbsp;545-552.&nbsp;&nbsp;1997</span></p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 10pt; font-family: 'Times New Roman';"><span style="font-size: 12pt; font-family: Cambria;">22.&nbsp;Recht J, Dunn B,&nbsp;<strong>Raff A</strong>, Osley M.&nbsp;&nbsp;Functional analysis of histone H2A and H2B in transcriptional repression in&nbsp;<em>Saccharomyces cerevisiae. Molecular and Cellular Biology</em>, 16(6):&nbsp;&nbsp;2545-2553<em>.</em>&nbsp;&nbsp;1996</span></p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 10pt; font-family: 'Times New Roman';"><span style="font-size: 12pt; font-family: Cambria;">23.&nbsp;Kopczynski J,&nbsp;<strong>Raff A</strong>, Bonner J.&nbsp;&nbsp;Translational readthrough at nonsense mutations in the&nbsp;<em>HSF1</em>&nbsp;gene of&nbsp;<em>Saccharomyces cerevisiae.&nbsp;</em>&nbsp;<em>Molecular and General Genetics</em>, 234: 369-378.&nbsp;&nbsp;1992</span></p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: Cambria;"><span style="font-family: 'Times New Roman';">&nbsp;</span></p>

EMR ID

4469

Biography

<p>Amanda C. Raff, MD, is Attending Physician, Professor and Associate Chair of Medicine for Undergraduate Medical Education at Montefiore-Einstein. She is also the co-director of the Montefiore-Einstein Autosomal Dominant Polycystic Kidney Disease Program. Dr. Raff&rsquo;s clinical focus is on dialysis and the treatment of patients with chronic kidney disease and end stage kidney disease.</p><p>After earning her Bachelor of Science in biology at Indiana University, Dr. Raff completed her Doctor of Medicine at Albert Einstein College of Medicine, earning her degree in 1998.&nbsp; Her postdoctoral training began at New York Presbyterian Hospital with an internship and residency in internal medicine from 1998 through 2001. She was assistant chief resident at Memorial Sloan Kettering Cancer Center in 2000 and chief resident at New York University Downtown Hospital from 2001 to 2002. She then returned to Montefiore-Einstein to complete a two-year fellowship in nephrology in 2004.</p><p>Dr. Raff&rsquo;s research focuses on medical education. She has been the Course Director for the Einstein medical student Renal Course since 2007 and the Internal Medicine Clerkship and Acting Internship Director since 2012. Dr. Raff&rsquo;s contributions in the field of Medical Education include serving as a Nephrology section committee member for the American College of Physicians&rsquo; Medical Knowledge Self-Assessment Program (MKSAP) 19 and 20 as well as prior work as a Case Editor for Aquifer Internal Medicine and contributing author and reviewer for the Clerkship Directors in Internal Medicine (CDIM) curriculum revision.</p><p>An enthusiastic medical educator, Dr. Raff has received several awards for her teaching and in 2010 was inducted into the Leo M. Davidoff Society for outstanding achievement in the teaching of medical students. She is board certified and is a member the American Society of Nephrology and a fellow of the American College of Physicians.</p>

Visit Type ID

2541

Is Open Scheduling

On

Cindy T. Pynadath

https://assets.montefioreeinstein.org/profiles/images/physphoto/Pynadath_Cindy_DO_420x504.jpg

First Name

Cindy

Last Name

Pynadath

NPI

1205062460

Faculty ID

16837

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Kidney and Pancreas Transplantation

Research Focus

Dr. Pynadath&rsquo;s current research interest in Transplant Medicine explores its connection to infectious disease and mineral bone and metabolic disorders, as well as the clinical outcomes in kidney transplant.&nbsp; Her work collaborations have been published in reputed journals, as well as presented at national and international transplant conferences.&nbsp;&nbsp;

Elsevier Profile

EMR ID

7261

Biography

<p>Cindy T. Pynadath, DO, is a Transplant Nephrologist and Assistant Professor, Medicine at Montefiore Einstein. Her clinical focus centers on kidney and pancreas transplantation.</p><p>After obtaining her Bachelor of Science in integrated life sciences from Kent State University in 2005, Dr. Pynadath earned her Doctor of Osteopathic Medicine at Ohio University College of Osteopathic Medicine in 2009. She then completed her internal medicine residency at the Cleveland Clinic Foundation in 2012 before completing a nephrology fellowship at University Hospitals Case Medical Center in 2014. Following this, Dr. Pynadath completed a transplant nephrology fellowship at the same institution in 2015.</p><p>Dr. Pynadath&rsquo;s current research in transplant medicine explores its connection to infectious disease and mineral bone and metabolic disorders, as well as the clinical outcomes in kidney transplantation. Her work collaborations have been published in a number of reputed journals, as well as presented at national and international transplant conferences.</p><p>Dr. Pynadath is board certified by the American Board of Internal Medicine. She is a member of multiple professional associations including the American Society of Transplantation (AST) and the American Society of Nephrology (ASN). She is a past recipient of the Caregiver Celebrations Appreciation Award for exemplary clinical and patient care from the Cleveland Clinic Foundation.</p>

Is Open Scheduling

Off

James M. Pullman

https://assets.montefioreeinstein.org/profiles/images/physphoto/Pullman_James_M_MD_PhD_11113785.jpg

First Name

James

Last Name

Pullman

NPI

1376623868

Faculty ID

11852

CMO Specialties

Clinical Terms

Employment Status

Per Diem

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Areas

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

4377

Is Open Scheduling

Off

Garrison Pease

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/b3b813e0-c4a7-11eb-925b-439657343c68.jpg

First Name

Garrison

Last Name

Pease

NPI

1598104721

Faculty ID

16562

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Genitourinary/Urologic (prostate, kidney, bladder, testicle, penis, adrenal gland) Pathology, with focus on one-on-one teaching at the scope with residents and medical students, along with quality assurance and quality improvement mind-set with emphasis on lab efficiency and patient-centered turn-around time.<quillbot-extension-portal></quillbot-extension-portal>

Research Focus

Genitourinary/Urologic Pathology, Quality Assurance and Improvement<quillbot-extension-portal></quillbot-extension-portal>

Elsevier Profile

EMR ID

113941

Biography

<p>Garrison Pease, MD, is an attending surgical pathologist and Assistant Professor, Pathology at Montefiore Einstein. His clinical focus centers on genitourinary and urologic pathology, with a focus on one-on-one teaching at the scope with residents and medical students. He is also focused on quality assurance and quality improvement with an emphasis on lab efficiency and patient-centered turn-around time.</p><p>After obtaining his Bachelor of Arts in biology from Saint John's University (Collegeville, MN) in 2009, Dr. Pease earned his Doctor of Medicine at the University of Minnesota in 2013. He completed his anatomic and clinical pathology residency at the University of University of Chicago - NorthShore in 2017, where he was Chief Resident in his final two years. Following this, Dr. Pease completed a general surgical pathology fellowship at Washington University &ndash; St. Louis in 2018, followed by a genitourinary pathology fellowship at the University of Washington in 2019.</p><p>Dr. Pease&rsquo;s research is focused on genitourinary and urologic pathology and quality assurance and improvement. He has worked on the College of American Pathologists (CAP) self and peer-based laboratory inspections. His work has been published in several peer-reviewed journals and shared through abstracts and poster presentations nationally and internationally.</p><p>Dr. Pease is a Diplomate of the American Board of Pathology and is board certified in Anatomic and Clinical Pathology. He is a member of the United States and Canadian Academy of Pathology and the College of American Pathologists. In 2021, Dr. Pease won the Department of Pathology Outstanding Teaching Award from Montefiore Einstein's Pathology Residency program.</p>

Is Open Scheduling

Off

Stuart Packer

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/0d90dcb0-3939-11ed-9b41-f32856b0701a.jpg

First Name

Stuart

Last Name

Packer

NPI

1124059621

Faculty ID

13484

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Stuart Packer, MD, is a medical oncologist with extensive experience in treating lung, head and neck, prostate and other types of cancer. After graduating magna cum laude from Case Western Reserve University, Dr. Packer received his medical degree from the State University of New York/Downstate Medical Center. He went on to complete a residency in medicine and fellowship in hematology/medical oncology at Duke University Medical Center. Since then Dr. Packer has held clinical and teaching positions at leading cancer centers, including Memorial Sloan-Kettering Cancer Center, Mount Sinai School of Medicine and Montefiore Einstein Center for Cancer Care.</p>
<p>Dr. Packer&rsquo;s clinical expertise is in medical management of lung cancer, head and neck cancer and prostate cancer. He is director of the melanoma and sarcoma programs at Montefiore Einstein Center for Cancer Care. In addition, Dr. Packer is medical director of Montefiore&rsquo;s Oncology Care Model (OCM), an alternative payment model sponsored by the Centers for Medicare and Medicaid Services and aimed at improving patient care coordination and appropriateness of care.</p>
<p>Dr. Packer is the author or co-author of medical textbook chapter and articles in peer-reviewed journals, including <em>Cancer, Clinical Cancer Research, British Medical Journal</em> and <em>Lung Cancer</em>. He is a member of the American Society of Clinical Oncology and the American Society of Hematology.</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Dr. Packer&rsquo;s clinical expertise is in medical management of lung cancer, head and neck cancer and prostate cancer.

Elsevier Profile

EMR ID

5497

Biography

<p>Stuart Packer, MD, is a medical oncologist with extensive experience in treating lung, head and neck, prostate and other types of cancer. After graduating magna cum laude from Case Western Reserve University, Dr. Packer received his medical degree from the State University of New York/Downstate Medical Center. He went on to complete a residency in medicine and fellowship in hematology/medical oncology at Duke University Medical Center. Since then Dr. Packer has held clinical and teaching positions at leading cancer centers, including Memorial Sloan-Kettering Cancer Center, Mount Sinai School of Medicine and Montefiore Einstein Center for Cancer Care.</p><p>Dr. Packer&rsquo;s clinical expertise is in medical management of lung cancer, head and neck cancer and prostate cancer. He is director of the melanoma and sarcoma programs at Montefiore Einstein Center for Cancer Care. In addition, Dr. Packer is medical director of Montefiore's Oncology Care Model (OCM), an alternative payment model sponsored by the Centers for Medicare and Medicaid Services and aimed at improving patient care coordination and appropriateness of care.</p><p>Dr. Packer is the author or co-author of medical textbook chapter and articles in peer-reviewed journals, including <em>Cancer</em>, <em>Clinical Cancer Research</em>, <em>British Medical Journal</em> and <em>Lung Cancer</em>. He is a member of the American Society of Clinical Oncology and the American Society of Hematology.</p>

Is Open Scheduling

Off